BioCryst Pharmaceuticals FY Conference Summary Company Overview - **Company**: BioCryst Pharmaceuticals (NasdaqGS: BCRX) - **Key Products**: ORLADEYO, navenibart - **Recent Acquisition**: Astria Therapeutics Financial Performance - **2025 Revenue**: $601 million from ORLADEYO, $563 million after excluding European business sale - **Operating Profit**: $214 million non-GAAP operating profits - **2026 Guidance**: $625 million to $645 million, representing a 13% growth over the previous year [4][28] Product Insights ORLADEYO - **Launch Dynamics**: - ORLADEYO is the only oral prophylactic treatment on the market, differentiating it from injectables [12] - Approximately 50% of patients switching to ORLADEYO are coming from injectable therapies [12] - 60% of patients who try ORLADEYO remain on it after one year [8] - **Super-Responders**: - Over 50% of clinical trial participants remained on ORLADEYO for two years, showing a 91% reduction in attacks [7] - Patients prefer oral administration, leading to high retention rates among super-responders [34] - **Pediatric Launch**: - Approval for pediatric use in December, with expectations of significant adoption due to the convenience of ORLADEYO pellets [20] - Current pediatric treatment is underdiagnosed and undertreated, with only 40% of diagnosed children receiving prophylaxis [19] Navenibart - **Acquisition Rationale**: - Navenibart offers a long-acting injectable option, requiring only 2-4 injections per year, which is appealing to patients currently on more frequent injectable therapies [45] - Phase 1b/2 data shows a 92% reduction in attacks for 3-month dosing and 90% for 6-month dosing [46] - **Market Positioning**: - Navenibart is expected to attract patients currently satisfied with injectables due to its efficacy and reduced injection frequency [47] - The product is anticipated to launch within the existing BioCryst portfolio, leveraging established patient loyalty [58] Market Dynamics - **Patient Growth**: - The number of diagnosed HAE patients is growing at approximately 3% annually, with significant potential for further diagnosis and treatment [60] - Current estimates suggest around 1,100 pediatric patients should be diagnosed, with many still untreated [19][61] - **Competitive Landscape**: - The market is becoming increasingly competitive with new entrants, but BioCryst's established presence and patient loyalty provide a competitive edge [56] Future Outlook - **Long-Term Projections**: - BioCryst anticipates a revenue growth rate in the mid-teens through the 2030s, supported by strong patent protection for both ORLADEYO and navenibart [63] - The company is focused on maintaining operational efficiency without the need for additional sales or marketing teams for navenibart [64] - **Pipeline Developments**: - Ongoing studies for KLK5 inhibitor for Netherton's disease, with results expected by year-end [65][68] - Plans to enhance market-building activities upon successful drug development [72] Key Risks and Considerations - **Guidance Caution**: - The 2026 guidance is considered conservative due to the absence of last year's Medicare payer tailwinds and the sale of the European business [28][29] - **Market Adoption Uncertainty**: - The speed of pediatric adoption and the overall market response to navenibart remain uncertain [22][27] Conclusion - BioCryst Pharmaceuticals is positioned for growth with its unique product offerings and strategic acquisitions, although it faces challenges in market dynamics and patient adoption rates. The company’s focus on maintaining a strong pipeline and leveraging existing patient relationships will be crucial for its future success.

Group 1 - BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is recognized as a promising small-cap stock with significant growth potential, receiving a Buy rating from Evercore ISI with a price target of $17.00 and a reaffirmed Buy rating from Bank of America Securities with a price target of $15.00 [1][2] - The company completed its acquisition of Astria Therapeutics, Inc. on January 23, which enhances its leadership in hereditary angioedema (HAE) and supports its long-term growth strategy [2] - BioCryst has added navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 clinical development, to its HAE portfolio, which aims to improve treatment experiences for HAE patients with potential dosing every three to six months [3] Group 2 - BioCryst Pharmaceuticals specializes in structure-guided drug design to develop oral small-molecule and protein therapeutics targeting rare diseases that are difficult to treat [4]

Core Insights - BioCryst Pharmaceuticals received FDA approval for ORLADEYO oral pellets for children aged 2 to less than 12 in December 2025, addressing a significant unmet need in hereditary angioedema (HAE) treatment [1] - The company reported strong financial performance for 2025, with ORLADEYO revenue reaching $601.8 million, a 38% increase year-over-year, and expects continued growth in 2026 [3][4] - BioCryst is advancing its pipeline, including navenibart, which is in pivotal Phase 3 trials, and BCX17725 for Netherton syndrome, with promising early results [6][10] Financial Performance - ORLADEYO revenue for 2025 was $601.8 million, up 38% year-over-year, and 43% when excluding the European business sold in October [3][4] - Non-GAAP operating profit rose to $214 million, a 198% increase year-over-year, marking the highest in company history [13] - The company ended 2025 with $337.5 million in cash and investments and entered a $400 million financing facility with Blackstone Life Sciences [14] Product Development and Pipeline - Navenibart is currently enrolling in the Phase 3 Alpha Orbit trial, targeting approximately 145 patients by mid-2026, with a BLA submission expected after mid-2027 [4][6] - Phase 2 data for navenibart showed significant attack-rate reductions, with mean reductions of 90-92% [7] - The company is also advancing BCX17725 for Netherton syndrome, with completed Phase 1 trials showing safety and tolerability [10][11] Market Positioning and Strategy - BioCryst views the HAE market as "structurally segmented," emphasizing that treatment choices are driven by patient needs rather than a single efficacy leader [3] - The pediatric launch of ORLADEYO is included in 2026 guidance but is expected to be a small contributor in the near term [5] - The company implemented a 9% price increase for ORLADEYO in January, expecting to net about half of that increase [15]

Financial Data and Key Metrics Changes - BioCryst Pharmaceuticals reported full-year ORLADEYO revenue of $601.8 million, representing a 38% increase year-on-year and a 43% increase when excluding the European business sold in October [5][20] - Non-GAAP total revenue increased by 45% year-on-year, with non-GAAP ORLADEYO revenues rising by approximately $169 million or 43% year-on-year [20][21] - Non-GAAP operating profit surged to $214 million, marking a 198% increase year-on-year, the highest in the company's history [21][24] Business Line Data and Key Metrics Changes - The HAE portfolio saw significant growth, with ORLADEYO capsules for ages 12 and up and ORLADEYO Pellets for younger children being key products [7][9] - The pivotal trial for navenibart is progressing well, with a mean attack rate reduction of 92% for every three months dosing and 90% for every six months dosing reported [14][15] Market Data and Key Metrics Changes - The company anticipates full-year 2026 ORLADEYO revenues to be between $625 million and $645 million, representing approximately 13% growth over 2025 revenues adjusted for Europe [24][25] - The pediatric market for ORLADEYO is expected to grow significantly, with the potential to double the number of diagnosed children and treatment rates [77] Company Strategy and Development Direction - BioCryst aims to remain a profitable rare disease company focused on commercialization, innovation, and disciplined clinical development [5][6] - The company is committed to capital allocation that drives long-term value creation and plans to terminate programs lacking a compelling path forward [22][24] - The strategy includes maintaining a strong focus on the HAE market, with a portfolio of differentiated products to meet diverse patient needs [6][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve blockbuster potential for ORLADEYO and highlighted the importance of patient growth and market dynamics [25][26] - The company is optimistic about the launch of ORLADEYO Pellets for children and the ongoing development of navenibart and BCX-17725 [12][89] Other Important Information - The company ended the year with a strong liquidity position of $337.5 million in cash and investments [24] - BioCryst entered into a $400 million financing facility with Blackstone Life Sciences to support growth initiatives [24] Q&A Session Summary Question: Timing for navenibart regulatory submission - Management confirmed that everything is on track for filing by the end of next year, with approval expected by late 2028 [31][33] Question: Predicting super responders for ORLADEYO - There is no way to predict super responders; patients must try the medication to determine their response [37][39] Question: Impact of new entrants on ORLADEYO - Management noted that new entrants are not expected to impact ORLADEYO negatively, as patients prefer oral prophylaxis over injectables [70][71] Question: ORLADEYO price increase and growth levers - A 9% price increase was implemented, with a focus on net patient growth as the primary KPI for achieving long-term revenue goals [75][76] Question: Netherton syndrome trial data release - Management plans to release data from both parts 3 and 4 of the Netherton syndrome trial together [57][58]

Core Insights - BioCryst Pharmaceuticals achieved full-year profitability for the first time in its history in 2025, driven by strong commercial execution and the highest level of new patient prescriptions for ORLADEYO in the U.S. since its launch [3] - The company maintained its revenue guidance for ORLADEYO in 2026, expecting between $625 million and $645 million [14][15] - BioCryst completed the acquisition of Astria Therapeutics, enhancing its hereditary angioedema (HAE) portfolio [3][4] Financial Performance - Total revenues for 2025 were $874.8 million, a significant increase from $450.7 million in 2024, with an operating profit of $341.0 million compared to an operating loss of $2.5 million in the previous year [6] - On a non-GAAP basis, total revenues were $592.9 million, reflecting a 45% year-over-year increase, and operating profit was $214.2 million, up 198% year-over-year [6][5] - The company recognized $243.3 million in revenue from the sale of its European ORLADEYO business [6] Business Developments - In October 2025, BioCryst sold its European ORLADEYO business to Neopharmed Gentili S.p.A., allowing for a streamlined operational structure focused on the U.S. market [4] - The FDA approved ORLADEYO oral pellets for children aged 2 to <12 years, marking it as the first targeted oral prophylactic therapy for this age group [4] - The acquisition of Astria Therapeutics included navenibart, an injectable monoclonal antibody currently in Phase 3 clinical development for HAE prophylaxis [4] Research and Development - Research and development expenses for 2025 were $136.6 million, a decrease of 5% year-over-year, reflecting increased program costs for BCX17725 and avoralstat, offset by lower personnel costs [7] - The Phase 3 program for navenibart is on track to support regulatory filing by the end of 2027, with positive interim results showing significant HAE attack suppression [4] Expense Overview - Sales and marketing expenses increased to $177.1 million, a 16% year-over-year rise, driven by distribution costs and pediatric launch support [8] - General and administrative expenses rose to $116.0 million, a 45% increase year-over-year, attributed to compensation and headcount growth [9] Financial Outlook - The company expects total revenue for 2026, including RAPIVAB®, to be between $635 million and $660 million, with non-GAAP operating expenses projected between $450 million and $470 million [14][15]

Core Insights - BioCryst Pharmaceuticals will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 AAAAI Annual Meeting in Philadelphia from February 27 to March 2, 2026 [1][2] HAE Portfolio Developments - Six abstracts will focus on new clinical trial and real-world outcomes with ORLADEYO (berotralstat), the first targeted oral prophylactic therapy for HAE patients aged 2 and older [2] - Three abstracts will present new clinical trial outcomes with navenibart, a long-acting monoclonal antibody plasma kallikrein inhibitor [2] - A late-breaking presentation will highlight positive interim results from the ALPHA-SOLAR trial, showing sustained HAE attack suppression with navenibart administered every 3 or 6 months [2][4] Strategic Focus - The data presented reflects BioCryst's strategy to expand and diversify its HAE portfolio, aiming to provide meaningful treatment options that align with patient needs [3] - The company is advancing programs like navenibart and launching an expanded pediatric indication for ORLADEYO [3] Presentation Details - BioCryst will present eight posters on February 27, 2026, and one late-breaking abstract on March 1, 2026, at the Convention Center, Level 2, Hall E [4] Product Information - ORLADEYO (berotralstat) is the first oral therapy specifically designed to prevent HAE attacks in patients aged 2 years and older [5] - Navenibart is an investigational monoclonal antibody being evaluated for long-term prevention of HAE attacks, with potential dosing every 3 or 6 months [6] Research Findings - Interim data from the APeX-P trial indicates that oral berotralstat reduces the rate of moderate and severe attacks in children aged 2 to less than 12 years [7] - Various posters will present real-world evidence on the impact of berotralstat on attack rates and healthcare resource utilization among patients with C1-inhibitor deficiency [7]

Company Overview - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) specializes in treatments for rare diseases, including an oral medication for hereditary angioedema and an injectable flu therapy [3] - The company is also engaged in discovering and testing new drugs for allergic and immunological conditions [3] Recent Developments - On January 23, BioCryst finalized a $700 million acquisition of Astria Therapeutics, which adds navenibart to its portfolio [3] - Navenibart is a long-acting Phase 3 therapy for hereditary angioedema, a rare genetic condition causing sudden, painful swelling [3] Market Sentiment - Jim Cramer expressed a negative outlook on BioCryst, advising investors to stay away from the stock, indicating it has been underperforming for a long time [1] - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to BioCryst [4]

Core Insights - BioCryst Pharmaceuticals has completed the acquisition of Astria Therapeutics, enhancing its leadership in hereditary angioedema (HAE) and supporting long-term growth [1][5] Acquisition Details - The acquisition was valued at approximately $700 million, financed through cash on hand and a financing facility, with BioCryst issuing about 37.3 million shares to Astria's equity holders [5] Product Portfolio Enhancement - BioCryst adds navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 development, which could be the first HAE therapy with every-three and every-six month dosing, improving patient treatment experiences [2][3] - The company now offers both the leading oral therapy (ORLADEYO®) and a potentially best-in-class injectable option, providing optimal choices for individualized patient care [3] Strategic Leadership Changes - Jill C. Milne, Ph.D., co-founder and CEO of Astria, has joined BioCryst's Board of Directors, while John Ruesch has been appointed as Chief Technical Operations Officer, bringing expertise in product development [6] Additional Programs - BioCryst has acquired Astria's early-stage program for atopic dermatitis, STAR0310, and plans to explore strategic alternatives for this program [4]

Financial Performance and Outlook - BioCryst achieved its first full year of profitability in 2025[13] - Preliminary ORLADEYO revenue for 2025 reached $601 million, with $563 million excluding European revenue[14] - The company anticipates ORLADEYO revenue between $625 million and $645 million in 2026[14] - Total revenue for 2026 is projected to be in the range of $635 million to $660 million[14] - Non-GAAP operating expenses for 2026 are expected to be between $380 million and $390 million, and $450 million to $470 million including the Astria acquisition[14] - BioCryst expects to have a cash balance of over $1 billion by 2029[37,52] Strategic Initiatives and Pipeline - BioCryst is acquiring Astria Therapeutics for approximately $700 million TEV to strengthen its HAE portfolio with navenibart[35] - ORLADEYO has a sustainable peak revenue opportunity of $1 billion, with IP protection extending into 2040[20] - The company received FDA approval for ORLADEYO pellet formulation for pediatric patients aged 2 to under 12 with HAE[13] - BCX17725 is being developed as a targeted KLK5 inhibitor for Netherton syndrome, with Phase 1 data from Part 4 expected by the end of 2026[54,69]

Group 1: Artiva Biotherapeutics - Artiva is developing AlloNK, a natural killer (NK) cell-based therapy for autoimmune diseases and cancers, with ongoing clinical trials for conditions like refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) [2][6] - The FDA granted Fast Track designation to AlloNK for refractory RA, highlighting its potential to meet the needs of over 150,000 U.S. patients who have not responded to existing treatments [6] - Recent data from 32 patients treated with AlloNK showed no cases of cytokine release syndrome or neurotoxicity, with all patients achieving complete B-cell depletion by Day 13 [7] Group 2: Market Potential and Analyst Ratings - Wedbush analyst Martin Fan projects a price target of $23 for Artiva, indicating a potential upside of approximately 600% over the next 12 months, supported by a Strong Buy consensus from analysts [10] - The SPDR S&P Biotech ETF (XBI) has increased by about 37% year-to-date, suggesting a growing interest in the biotech sector amid a pause in AI market leadership [4] - Artiva's shares are currently trading at $3.30, which is below its cash value of $5 per share, indicating potential for substantial appreciation as clinical data emerges [10] Group 3: BioCryst Pharmaceuticals - BioCryst has transitioned into a profitable biotech company, driven by its focus on rare diseases and the success of its drug Orladeyo, which generated $159.1 million in net revenue for Q3 2025, a 37% year-over-year increase [14][15] - The FDA recently approved an oral pellet formulation of Orladeyo for pediatric patients, expanding its market reach and potential revenue, with estimates suggesting it could generate $1 billion in peak annual revenue by 2029 [15] - BioCryst's stock is trading at $7.57, with an average price target of $19.27, implying a potential gain of 154% over the next 12 months, supported by a Strong Buy consensus from analysts [19]